]>
IRCT20181014041334N1 IRCT 2018-12-02 Oroumia University of Medical Sciences Comparing the effectiveness of three therapeutic drug regimen for the treatment of a withdrawal headache Evaluate the comparative effectiveness of three therapeutic drug regimen for the treatment of a withdrawal headache in patients with medication overuse headache, referring to the neurology clinic 2018-11-06 anticipated 60 Complete https://irct.ir/trial/34628 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: For each group, there will be 10 envelopes for men and 10 envelopes for women containing the group number (20 envelopes for each group). The Clinic Clerk will randomly pick up an envelope from one group for delivery to the eligible patient. For women, this should be the same. At the same time, one Female person within a group should be entered in parallel with one male one, until finally, 10 men and 10 women will be enrolled in the study within each group. 2-3 Medication Overuse Headache (MOH). Intervention 1: Intervention group: celecoxib (100 mg, Cap, Iran, Tehran, Daru Pars, celecoxib 100 mg three times daily for the first five days, 100 mg twice daily (five days later) and 100 mg once a day (five The next day). Intervention 2: Intervention group: Prednisolone Tablets (Aburaihan Pharmaceutical, Iran, Tehran, .Co, 50 mg, 5 mg) 75 mg (three first days) 50 mg (three days later) 30 mg (three The next day (25 mg three days later) and 10 mg (the last 3 days). Intervention 3: Intervention group: celecoxib 100 mg three times daily + 75 mg prednisolone for the first 4 days, celecoxib 100 mg twice daily + 50 mg prednisolone for the second 4 days, celecoxib 100 mg once daily + 25 mg prednisolone for 4 days, 100 mg once daily + 10 mg prednisolone for 3 last day. Yes - There is a plan to make this available What will be shared: Moh data When: year To whom: scientific valid researchers Conditions: with authority Where to obtain: Dr chehregani email How to obtain: should be requested via email or valid scientific web site such as research gate Comments:
public Dr Afshin Chehreghani
Ershad
urmia Iran (Islamic Republic of) 5714783734 +98 44 3223 4897 afshin.chehregani@gmail.com Oroumia University of Medical Sciences scientific Dr. Arash Mosarrezaii
Ershad
Urmia Iran (Islamic Republic of) 5714783734 +98 44 3223 4897 mosarrezaii.a@umsu.ac.ir Oroumia University of Medical Sciences Iran (Islamic Republic of) age between 18 to50 year Patients with headache more than 15 days per month A history of regular use of one or more symptomatic treatment medications over a period of more than a month, including ergotamine, tryptan, combination of analgesic drugs (simple and combination), tryptones, ergotamine and narcotics (more than 10 days per month for more than 3 months), or analgesic drugs Simple such as acetaminophen or NSAIDs (10 days per month in regular three months) A headache that progresses or gets worse in the course of drug abuse lack of mental psychological illness no pregnancy No previous history or disease has been detected not having platelet disorders 18 years 50 years Both lack of referral for the follow up Arbitrary discontinuation of patient medication G44 Other headache syndromes Treatment - Drugs Treatment - Drugs Treatment - Drugs Intervention group: celecoxib (100 mg, Cap, Iran, Tehran, Daru Pars, celecoxib 100 mg three times daily for the first five days, 100 mg twice daily (five days later) and 100 mg once a day (five The next day) Intervention group: Prednisolone Tablets (Aburaihan Pharmaceutical, Iran, Tehran, .Co, 50 mg, 5 mg) 75 mg (three first days) 50 mg (three days later) 30 mg (three The next day (25 mg three days later) and 10 mg (the last 3 days) Intervention group: celecoxib 100 mg three times daily + 75 mg prednisolone for the first 4 days, celecoxib 100 mg twice daily + 50 mg prednisolone for the second 4 days, celecoxib 100 mg once daily + 25 mg prednisolone for 4 days, 100 mg once daily + 10 mg prednisolone for 3 last day Headache severity. Timepoint: 15 days. Method of measurement: VAS. Headache duration. Timepoint: daily. Method of measurement: headache duration (days). Drug dependence reduction. Timepoint: 15 days. Method of measurement: Used Drug Dosage. Oroumia University of Medical Sciences Approved 2018-05-30 Urmia Medical Science University Ethical committee Resalat Urmia West Azarbaijan Iran (Islamic Republic of)